Blog

Petros Grivas/fredhutch.org

Dec 8, 2024, 07:13

Petros Grivas: Great to present TROPiCS04 trial at ESMOAsia24

Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, reshared the post on X by Roberto Iacovelli, Medical oncologist at Fondazione Policlinico Gemelli IRCCS in Rome, adding:

“Great to be in Singapore.

The European Society for Medical Oncology (ESMO) ESMOAsia24 presented TROPiCS04 trial:

higher ORR (23% vs 14%) and CBR (30% vs 21%) with SG vs TPC, higher neutropenia-related AEs, only ~20% with primary G-CSF prophylaxis (50% subsequent Tx) -> no significant OS benefit by Tom Powles and Terry Friedlander.”

Petros Grivas

Quoting Roberto Iacovelli’s post:

“It’s happening now, Petros Grivas is presenting results of TROPICS04 at ESMOAsia24.”

Petros Grivas

Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Dr. Roberto Iacovelli, is a medical oncologist at Fondazione Policlinico Gemelli IRCCS in Rome, Italy. With a focus on genitourinary cancers, his research focuses on metastatic renal cell carcinoma, prostate, and bladder cancer, exploring predictive factors and therapy sequencing. Dr. Iacovelli’s contributions include over 150 publications in peer-reviewed journals and numerous awards for his work, including the ASCO Cancer Foundation Merit Award in 2011.

More posts featuring Petros Grivas.